- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT06596694
Studie Patritumab Deruxtecan u účastníků s rakovinou trávicího traktu (MK-1022-011)
Studie fáze 1/2 k vyhodnocení bezpečnosti a účinnosti Patritumab Deruxtecan u rakoviny trávicího traktu
Researchers want to learn if patritumab deruxtecan (MK-1022) can treat certain gastrointestinal (GI) cancers. The GI cancers being studied are advanced (the cancer has spread to other parts of the body). The goals of this study are to learn:
- About the safety and how well people tolerate of patritumab deruxtecan
- How many people have the cancer respond (get smaller or go away) to treatment
Přehled studie
Postavení
Podmínky
Intervence / Léčba
Typ studie
Zápis (Odhadovaný)
Fáze
- Fáze 2
- Fáze 1
Kontakty a umístění
Studijní místa
-
-
New South Wales
-
Sydney, New South Wales, Austrálie, 2145
- Westmead Hospital ( Site 0100)
-
-
Victoria
-
Melbourne, Victoria, Austrálie, 3004
- Alfred Health ( Site 0102)
-
Melbourne, Victoria, Austrálie, 3084
- Austin Health ( Site 0103)
-
-
Western Australia
-
Mount Pleasant, Western Australia, Austrálie, 6009
- One Clinical Research ( Site 0104)
-
-
-
-
Region M. de Santiago
-
Santiago, Region M. de Santiago, Chile, 8420383
- Bradfordhill ( Site 0300)
-
Santiago, Region M. de Santiago, Chile, 7500921
- Fundacion Arturo Lopez Perez ( Site 0301)
-
Santiago, Region M. de Santiago, Chile, 7560908
- Centro de Oncología de Precisión ( Site 0305)
-
Santiago, Region M. de Santiago, Chile, 7620002
- Clínica UC San Carlos de Apoquindo ( Site 0302)
-
-
-
-
Auvergne-Rhône-Alpes
-
Lyon, Auvergne-Rhône-Alpes, Francie, 69004
- Hopital de la Croix Rousse ( Site 0502)
-
-
Hauts-de-Seine
-
Clichy, Hauts-de-Seine, Francie, 92110
- Hopital Beaujon ( Site 0500)
-
-
Ille-et-Vilaine
-
Rennes, Ille-et-Vilaine, Francie, 35042
- Centre Eugène Marquis Rennes - Centre de Lutte Contre le Cancer ( Site 0501)
-
-
-
-
-
Milan, Itálie, 20133
- Fondazione IRCCS Istituto Nazionale dei Tumori ( Site 0700)
-
Milan, Itálie, 20162
- ASST Grande Ospedale Metropolitano Niguarda ( Site 0701)
-
Roma, Itálie, 00168
- Fondazione Policlinico Universitario Agostino Gemelli ( Site 0702)
-
-
-
-
-
Haifa, Izrael, 3109601
- Rambam Health Care Campus ( Site 0603)
-
Jerusalem, Izrael, 9112001
- Hadassah Medical Center ( Site 0602)
-
Tel Aviv, Izrael, 6423906
- Sourasky Medical Center ( Site 0601)
-
-
-
-
-
Seoul, Jižní Korea, 03722
- Severance Hospital, Yonsei University Health System ( Site 0903)
-
Seoul, Jižní Korea, 05505
- Asan Medical Center ( Site 0902)
-
Seoul, Jižní Korea, 06351
- Samsung Medical Center ( Site 0901)
-
-
Seoul
-
Seodaemun-gu, Seoul, Jižní Korea, 03080
- Seoul National University Hospital ( Site 0900)
-
-
-
-
Nova Scotia
-
Halifax, Nova Scotia, Kanada, B3H 2Y9
- QEII Health Sciences Centre - Victoria General Site ( Site 0200)
-
-
Ontario
-
Toronto, Ontario, Kanada, M4N 3M5
- Sunnybrook Research Institute - Odette Cancer Centre ( Site 0206)
-
-
Quebec
-
Montreal, Quebec, Kanada, H4A 3J1
- McGill University Health Centre ( Site 0202)
-
-
-
-
-
Auckland, Nový Zéland, 1023
- Harbour Cancer & Wellness ( Site 0800)
-
-
-
-
California
-
Santa Monica, California, Spojené státy, 90404
- UCLA Hematology Oncology Santa Monica ( Site 1205)
-
-
Colorado
-
Aurora, Colorado, Spojené státy, 80045
- University of Colorado Cancer Center ( Site 1200)
-
-
District of Columbia
-
Washington D.C., District of Columbia, Spojené státy, 20016
- Sibley Memorial Hospital ( Site 1208)
-
-
Florida
-
Gainesville, Florida, Spojené státy, 32610
- University of Florida ( Site 1202)
-
Miami Beach, Florida, Spojené státy, 33140
- Mount Sinai Medical Center Comprehensive Cancer Center ( Site 1213)
-
-
Georgia
-
Marietta, Georgia, Spojené státy, 30060
- Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research ( Site 1203)
-
-
Illinois
-
Chicago, Illinois, Spojené státy, 60637
- University of Chicago Medical Center ( Site 1204)
-
-
Nevada
-
Reno, Nevada, Spojené státy, 89502
- Renown Regional Medical Center ( Site 1221)
-
-
New York
-
Mineola, New York, Spojené státy, 11501
- NYU Langone Hospital - Long Island ( Site 1230)
-
New York, New York, Spojené státy, 10016
- Perlmutter NYU Cancer Center ( Site 1212)
-
-
Texas
-
Temple, Texas, Spojené státy, 76508
- Scott & White Medical Center-Temple ( Site 1224)
-
-
Virginia
-
Roanoke, Virginia, Spojené státy, 24014
- Oncology and Hematology Associates of Southwest Virginia (BRCC) ( Site 1207)
-
-
Wisconsin
-
Madison, Wisconsin, Spojené státy, 53792
- University of Wisconsin ( Site 1210)
-
-
-
-
-
Tainan, Tchaj-wan, 704
- National Cheng Kung University Hospital-Clinical Trial Center ( Site 1502)
-
Taipei, Tchaj-wan, 10002
- National Taiwan University Hospital ( Site 1500)
-
Taipei, Tchaj-wan, 112201
- Taipei Veterans General Hospital ( Site 1501)
-
-
-
-
Bangkok
-
Bangkoknoi, Bangkok, Thajsko, 10700
- Faculty of Medicine Siriraj Hospital ( Site 1301)
-
Ratchathewi, Bangkok, Thajsko, 10400
- Ramathibodi Hospital ( Site 1302)
-
-
-
-
-
Adana, Turecko (Türkiye), 01370
- Adana City Hospital ( Site 1404)
-
Ankara, Turecko (Türkiye), 06230
- Hacettepe Universite Hastaneleri ( Site 1401)
-
-
Ankara
-
Yenimahalle, Ankara, Turecko (Türkiye), 06200
- Dr. Abdurrahman Yurtaslan Ankara Onkoloji Egitim ve Arastırma Hastanesi ( Site 1400)
-
-
İzmir
-
Balçova, İzmir, Turecko (Türkiye), 35340
- Dokuz Eylul Universitesi Hastanesi ( Site 1402)
-
-
-
-
Anhui
-
Hefei, Anhui, Čína, 230088
- The First Affiliated Hospital of Anhui Medical University ( Site 0405)
-
-
Fujian
-
Fuzhou, Fujian, Čína, 350014
- Fujian Provincial Cancer Hospital ( Site 0408)
-
Xiamen, Fujian, Čína, 361015
- Zhongshan Hospital Fudan University (Xiamen Branch) ( Site 0412)
-
-
Guangdong
-
Fuzhou, Guangdong, Čína, 510515
- Southern Medical University Nanfang Hospital ( Site 0413)
-
Guangzhou, Guangdong, Čína, 510080
- The First Affiliated Hospital, Sun Yat-sen University ( Site 0404)
-
-
Guangxi
-
Nanning, Guangxi, Čína, 530200
- Affiliated Cancer Hospital of Guangxi Medical University ( Site 0411)
-
-
Henan
-
Zhengzhou, Henan, Čína, 450008
- Henan Cancer Hospital ( Site 0403)
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Čína, 200032
- Zhongshan Hospital,Fudan University ( Site 0400)
-
-
Shanxi
-
Taiyuan, Shanxi, Čína, 030001
- First Hospital of Shanxi Medical University ( Site 0409)
-
-
-
-
-
Barcelona, Španělsko, 08035
- Hospital Universitari Vall d Hebron ( Site 1000)
-
Madrid, Španělsko, 28007
- Hospital Universitario Gregorio Maranon ( Site 1002)
-
Madrid, Španělsko, 28040
- Hospital Clinico San Carlos... ( Site 1003)
-
-
Principality of Asturias
-
Oviedo, Principality of Asturias, Španělsko, 33011
- Hospital Central de Asturias ( Site 1001)
-
-
-
-
-
Geneva, Švýcarsko, 1211
- Hopitaux Universitaires de Geneve HUG. ( Site 1102)
-
Zurich, Švýcarsko, 8091
- Universitaetsspital Zuerich ( Site 1105)
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
The main inclusion criteria include but are not limited to the following:
-
Has one of the following cancers:
- Unresectable or metastatic colorectal cancer.
- Advanced and/or unresectable biliary tract cancer (BTC)
- Hepatocellular carcinoma (HCC) not amenable to locoregional therapy
- Locally advanced unresectable or metastatic gastroesophageal cancer
-
Has received prior therapy for the cancer.
-
Has recovered from any side effects due to previous cancer treatment
Exclusion Criteria:
The main exclusion criteria include but are not limited to the following:
- Has a history of (noninfectious) interstitial lung disease (ILD) or pneumonitis that required steroids, or has current ILD or pneumonitis, and/or suspected ILD or pneumonitis that cannot be ruled out by standard diagnostic assessments at Screening
- Has clinically severe respiratory compromise (based on the investigator's assessment) resulting from intercurrent pulmonary illnesses
- Has evidence of any leptomeningeal disease
- Has clinically significant corneal disease
- Has uncontrolled, significant cardiovascular disease or cerebrovascular disease
- Has evidence of ongoing uncontrolled systemic bacterial, fungal, or viral infection
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: N/A
- Intervenční model: Přiřazení jedné skupiny
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: Patritumab deruxtecan
Participants receive patritumab deruxtecan intravenous (IV) infusion on Day 1 of each 21-day cycle (every 3 weeks) until disease progression, intolerable toxicity, or investigator decision. |
Administered via intravenous (IV) infusion
Ostatní jména:
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Number of Participants Experiencing Dose-Limiting Toxicity (DLT) (Dose-Escalation Phase)
Časové okno: Up to 21 days
|
DLT will be defined as any drug-related adverse event observed during the DLT evaluation period that results in a change to a given dose or a delay in initiating the next 21-day cycle. The number of participants in the dose-escalation phase who experience a DLT will be presented. |
Up to 21 days
|
|
Number of Participants with One or More Adverse Events (AEs)
Časové okno: Up to approximately 44 months
|
An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who experience an AE will be presented. |
Up to approximately 44 months
|
|
Number of Participants who Discontinue Study Intervention Due to an AE
Časové okno: Up to approximately 44 months
|
An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who discontinue study treatment due to an AE will be presented. |
Up to approximately 44 months
|
|
Objective Response Rate (ORR)
Časové okno: Up to approximately 44 months
|
ORR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. The percentage of participants who experience CR or PR as assessed by Blinded Independent Central Review (BICR) will be presented. |
Up to approximately 44 months
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Duration of Response (DOR)
Časové okno: Up to approximately 44 months
|
For participants who demonstrate a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. DOR as assessed by BICR will be presented. |
Up to approximately 44 months
|
|
Progression Free Survival (PFS)
Časové okno: Up to approximately 44 months
|
PFS is defined as the time from first day of study intervention to the first documented progressive disease (PD) or death due to any cause, whichever occurs first as assessed by BICR. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. The appearance of one or more new lesions is also considered PD. PFS as assessed by BICR will be presented. |
Up to approximately 44 months
|
|
Overall Survival (OS)
Časové okno: Up to approximately 44 months
|
OS is the length of time from when the participant starts treatment until death from any cause. |
Up to approximately 44 months
|
|
Maximum Plasma Concentration (Cmax) of Patritumab Deruxtecan
Časové okno: At designated time points (up to ~44 months)
|
Blood samples collected at protocol specific time points will be used to determine the Cmax of patritumab deruxtecan. |
At designated time points (up to ~44 months)
|
|
Trough Concentration (Ctrough) of Patritumab Deruxtecan
Časové okno: At designated time points (up to ~44 months)
|
Blood samples collected at protocol specific time points will be used to determine the Ctrough of patritumab deruxtecan. |
At designated time points (up to ~44 months)
|
Spolupracovníci a vyšetřovatelé
Sponzor
Spolupracovníci
Vyšetřovatelé
- Ředitel studie: Medical Director, Merck Sharp & Dohme LLC
Publikace a užitečné odkazy
Užitečné odkazy
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
Další identifikační čísla studie
- 1022-011
- MK-1022-011 (Jiný identifikátor: MSD)
- U1111-1305-0677 (Identifikátor registru: UTN)
- 2024-512442-41-00 (Identifikátor registru: EU CT)
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .